Intuitive Surgical (ISRG) — Q3 FY2026 Analyst Q&A Breakdown
Fiscal period: Q3 2026 · Report date: October 20, 2026
Q1 — Lawrence Biegelsen, Wells Fargo
The Question: U.S. da Vinci procedure growth of 10% — characterized by the analyst as the lowest since COVID (analyst-provided) and stable on a stacked two-year basis (analyst-provided) — despite strong shipments, heavy innovation, and the coming extended-use program. Is this a temporary lull, and will innovation plus the pricing actions accelerate U.S. procedures as soon as next year?
Management’s Response: Rosa reframed the U.S. opportunity as two parts: the addressable opportunity being pursued daily (significant in benign general surgery, where customers want clinical and economic comparisons against entrenched laparoscopy) and a longer-term opportunity in new indications. New color: in Q3 he met with about five large IDN customers who are now building their own real-time dashboards tracking da Vinci’s economics and outcomes against laparoscopy and open surgery routinely, rather than reviewing episodic annual data — and “robotics is comparing favorably.” Samath added four company-driven levers, with two genuinely new data points: U.S. net placements increased 41% this quarter, described as “a little bit of a change from what we’ve seen in more recent quarters,” and ASC placements over the last two quarters combined exceeded almost the prior three years. The other two levers — progressing cardiac and breast along the early-adoption curve, and R&D programs for new indications — sit on longer horizons.
The “Analyst’s Take”: Direct but number-light on the core question: neither executive promised reacceleration timing. Management let the “lowest since COVID” framing stand without disputing it, and answered with a framework plus capacity evidence — the 41% net-placement figure is the strongest implicit rebuttal offered. The IDN dashboard anecdote is the freshest signal that the economic argument for benign robotics is landing at the customer level.
Q2 — Robert Marcus, JPMorgan
The Question: A three-part turn on the instrument pricing actions (the extended-use program plus China): (a) implementation timelines and whether customers will stock up ahead of them; (b) how the impact flows down the P&L, gross margin and operating margin; (c) whether volumes respond — the 2020 program produced a price-elasticity benefit.
Management’s Response: On (a), Samath allowed “there may well be a little bit of stocking” as launch timing shifts ordering patterns, but not expected to be significant, and the company will call it out if it occurs. On (b), a new commitment: the gross-margin impact will be “modest” and looked across 2027 to be offset by the cost-reduction programs in play, so “whatever impact there is on gross margin can fall through to operating margin” — small and offset within the year. On (c), the clearest statement of intent on the call: “we believe that these actions will drive elasticity,” because they are applied where cost is a barrier, and the benefit for high-volume benign procedures is “quite a bit greater than the blended 3% to 5%”; the 2020 EUP data supports elasticity’s existence, but it “doesn’t obviously turn on immediately in 2027.” Rosa closed by rejecting the premise of a trade-off: da Vinci 5 innovation is priced in correlation with the value it creates.
The “Analyst’s Take”: The most substantive answer of the session — a gross-margin offset commitment and an explicit elasticity thesis, both new relative to prepared remarks. The confession that stocking may occur, however small, hands analysts a Q4/Q1 noise source to monitor. Rosa’s tag-on was strategy reinforcement rather than new information.
Q3 — Travis Steed, Bank of America
The Question: A pipeline question: with U.S. procedures getting the attention, what in the pipeline could add revenue per procedure — AI use cases, imaging, the GI robot, or lung cancer? (The analyst also noted this was probably the biggest quarterly buyback the company has ever done — a characterization of the company-disclosed $2.9 billion.)
Management’s Response: Rosa named concrete programs, the most specific pipeline disclosure of the call: on Ion, two active development programs — a ROSE system for on-site cytology, giving the care team real-time answers on whether cells may be cancer, and endobronchial ultrasound integrated into the Ion platform for staging. Both, he said, speed the path from detection to diagnosis and treatment and “will be accretive to the revenue per case on the Ion platform.” On da Vinci vision: multiple programs in advanced visualization — hyperspectral imaging, fluorescing molecules, and AI features — expected to bring incremental revenue per procedure.
The “Analyst’s Take”: Direct and additive: management effectively confirmed a revenue-per-procedure pipeline on both platforms, which matters as the 3–5% pricing headwind builds. No timelines were attached to any program, so the disclosure creates a watchlist rather than a schedule.
Q4 — Rick Wise, Stifel
The Question: A two-part turn: (a) ASC progress and what’s next, including how the next-generation extended-use approach affects the opportunity; (b) on competition — citing the Stryker CMR news (analyst-provided), two competitors are likely offering modular systems in the ASC: how do the dynamics play out, and does Intuitive need a modular offering?
Management’s Response: On (a), Rosa argued ASC customers are asking for repeatability, ease of learning and use, and reliability across a targeted procedure set — “it’s about volume and it’s about getting patients out in a repeatable, knowable way” — and framed the buying decision as architecture, a portfolio priced to their economics, the ecosystem, and supporting infrastructure. On (b), he disclosed that over 30 years Intuitive has “engineered and tested just about every form of architecture,” including modular and table-mounted systems with customers evaluating them side by side, and concluded a cart-based architecture “is the best balance of capability and usability” — a modular architecture is not required. Samath added the market-sizing numbers: a little under 10% of U.S. soft-tissue surgery is in ASCs today, about 70% of those volumes are in ASCs affiliated with existing IDNs, and Intuitive’s penetration of the full ASC opportunity is low — with XiR supply now available, it is a focus.
The “Analyst’s Take”: The competitive half was answered philosophically: Rosa never engaged with Stryker or CMR by name, converting “do you need modular?” into “what do ASC customers actually need?” — a confident but untested refusal to match entrants’ form factor. The ASC market-share disclosure (<10% penetration, IDN affiliation) was new and quantified the white space; the extended-use angle of the question went unaddressed.
Q5 — Adam Maeder, Piper Sandler
The Question: On EUP 2.0’s offsets: the analyst restated the headwind as 300–500 basis points (analyst-provided paraphrase of the company’s 3–5%) and noted no sensing-instrument offset appears assumed in it. Where is force-sensing adoption today, what share of procedures use it, and what are the primary use cases?
Management’s Response: Rosa led with a clinical anecdote: a prostatectomy surgeon with over 10,000 cases showed him return-of-potency data rising from about 50% out of the gate to above 80% at 12 months, with his recent da Vinci 5 experience shifting the entire curve up by about 10 points — attributed by the surgeon to force feedback enabling gentler nerve-sparing. Samath quantified adoption: about 8% of da Vinci 5 cases this quarter involved force feedback, a slow increase constrained by supply arriving late in the quarter, with ambitions for the penetration number to be “quite a bit higher” as supporting evidence is built. He then enumerated the offsets excluded from the 3–5% estimate: SP I&A per procedure runs above multi-port and those procedures are growing much faster; on da Vinci 5, integrated insufflation is used about 85% of the time and adds about $100 per procedure in connecting tube sets — offsets expected to grow faster than base I&A.
The “Analyst’s Take”: The 8% penetration figure and the $100 insufflation detail are the new data; management implicitly confirmed the analyst’s read that no sensing offset is embedded in the 3–5%. The potency-curve story is vivid but anecdotal — color standing in for the controlled evidence base the penetration number says doesn’t exist yet at scale.
Q6 — Jayson Bedford, Raymond James And Associates
The Question: On the EUP: how long to full implementation, when does the 3–5% impact on revenue per procedure fully hit, and can the 2027 impact be framed?
Management’s Response: Samath gave the sharpest timeline of the session: rollout is country by country, U.S. first — “sometime later in Q1” 2027, depending on 510(k) clearance — Europe next in the second half of 2027, and other markets just before or after that. His conclusion: “I don’t think we get to the full impact till the end of the year, frankly,” referring to 2027. No 2027 P&L framing beyond that was offered.
The “Analyst’s Take”: Direct, precise, and genuinely additive — this answer converts the prepared remark of “beginning in the first half of 2027” into a sequenced geography-by-geography schedule with an end-2027 full-run-rate date. The absence of a 2027 EPS-level framing stands, but the timing question was fully answered.
Q7 — Matt Taylor, Jefferies
The Question: On the settlement announced today: it is described as one-time, no-fault, and providing certainty — what does it practically mean for customers, and has third-party remanufacturing actually been any kind of real headwind?
Management’s Response: Rosa (inviting Chief Legal Officer Gary Loeb to add, who did not speak on the transcript) described the settlement as an agreement with customers specifically regarding third-party instrument remanufacturers and third-party service providers, establishing “a clear framework on how we’ll continue to work together in those two specific areas” and letting the company focus on advancing the safety, quality, and security of its products. Samath added that the resolution strengthens customer relationships and provides a defined framework for working together on instruments and services.
The “Analyst’s Take”: The second half of the question went unanswered: neither executive quantified or even characterized whether remanufacturing had been a real headwind. What remains is reassurance language — “certainty,” “framework,” “focus” — and a $450 million price tag for it (see the briefing’s settlement section), with the practical customer mechanics left at the framework level.
Q8 — Chris Pasquale, Barclays
The Question: On margins: acknowledging the company has done a great job improving profitability and that this quarter was better than expected (both analyst-provided), the analyst noted the Street is modeling operating margin flat next year (analyst-provided). Beyond offsetting the extended-use gross-margin headwind, what other considerations should shape expectations for continued margin expansion?
Management’s Response: Samath restated the company’s long-standing framework — an expected operating-margin range of 35% to 40%, which he called “frankly best in class in medtech” — and then confirmed the investment posture: at the current 41–42%, “we have the capacity to invest.” The planning process will evaluate where to spend it; he is “not ready to say what we’ll do on operating expenses,” with guidance coming in January. The strategic lean: invest in innovation and in supporting accelerated growth to serve more patients.
The “Analyst’s Take”: Direct but deliberately unfinished: the answer all but concedes margins can compress from today’s 41–42% toward the 35–40% band as management opts for investment over defense, without committing either way until January. The 35–40% range restatement is the anchor analysts should hold management to when 2027 guidance lands.
Count Check
8 entries vs. 8 question units in the transcript — the eight operator-introduced analyst turns (Biegelsen, Marcus, Steed, Wise, Maeder, Bedford, Taylor, Pasquale), each a single turn with no separate follow-ups; Rosa closed the session after the eighth.
Synthesis
Clusters
| Concern | Analysts (Q#s) | Uniform management answer | Signal |
|---|---|---|---|
| EUP 2.0 mechanics: timing, offsets, elasticity | Marcus (Q2), Maeder (Q5), Bedford (Q6) | 3–5% headwind, country-by-country from Q1 2027, full impact end-2027, offsets excluded but expected to accrete | Three of eight questions probed one program from three angles — the Street’s dominant 2027 modeling problem |
| U.S. procedure growth trajectory | Biegelsen (Q1) | Four-lever framework: capacity, ASC, early-stage categories, pipeline; no reacceleration date | Management answered the “when” with levers, a tell that near-term acceleration is not being promised |
| Margin trajectory into 2027 | Pasquale (Q8), Marcus (Q2, gross-margin part) | 35–40% long-term band; cushion available to invest; EUP hit offset by cost programs at the gross line | Willingness to let reported margin fall is explicit — the January guide is the decision point |
| ASC opportunity and competitive entry | Wise (Q4) | Cart-based architecture is sufficient; ecosystem and economics win; ASC white space quantified | New modular entrants drew a philosophy answer, not a counter-move |
Deflections
| Topic (Q#) | What was asked | Deflection technique |
|---|---|---|
| Modular competition (Q4) | Whether Stryker/CMR modular systems in the ASC force an architectural response | Reframed to customer needs and 30 years of architecture testing; competitors never named, need for modular flatly denied |
| 2027 operating margin (Q8) | Whether margin expansion continues next year | Deferred to January planning; restated the 35–40% band instead of engaging the Street’s flat-margin model |
| Remanufacturing impact (Q7) | Whether third-party servicing has been a real headwind | Not addressed — framework and certainty language substituted for any economic characterization |
| 2027 P&L framing (Q6) | Magnitude of the EUP impact within 2027 | Timing answered fully; magnitude left at the prepared-remarks 3–5% mix-constant figure |
Contradictions
| Contradiction | Prepared-remarks claim (Q#/source) | Q&A walk-back |
|---|---|---|
| Durability vs. sequencing of U.S. growth | Prepared remarks: breadth of adoption and the growing dV5/SP base “positions us for durable U.S. procedure growth over the long term” (Q1 context) | Q&A (Q1) located the drivers in capacity, ASC, and early-stage categories “on longer-term horizons” — durability affirmed, near-term acceleration quietly declined |
| Pricing headwind vs. offsets | Prepared remarks: 3–5% per-procedure reduction “once fully implemented,” mix-constant (Q2, Q5 context) | Q&A (Q5) revealed the excluded offsets — SP mix, insufflation tube sets, force feedback — that management expects to grow faster than base I&A, recasting the headwind as a gross figure before accretive items |
| Margin confidence vs. investment intent | Prepared remarks: 42% operating margin, gross margin guided up (Q8 context) | Q&A (Q8) reintroduced the 35–40% band and “capacity to invest,” signaling the peak margin is a spending opportunity, not a floor to defend |
Unanswered
- Rick Wise (Q4): how the extended-use program specifically affects the ASC opportunity — the question’s first half was absorbed into general ASC framing.
- Matt Taylor (Q7): whether third-party remanufacturing was ever a real headwind — no economic characterization or quantification was offered.
- Chris Pasquale (Q8): the actual direction of 2027 operating margin — deferred to January guidance.